Circulating donor-specific anti-HLA antibodies are a major factor in premature and accelerated allograft fibrosis

Kidney International

Volumn 92, Issue 3, 2017, Pages 729-742

  Gosset, Clément ^a,b   Viglietti, Denis ^a,b   Rabant, Marion ^c   Vérine, Jérôme ^b   Aubert, Olivier ^a   Glotz, Denis ^a,b   Legendre, Christophe ^a,c   Taupin, Jean Luc ^b   Duong Van Huyen, Jean Paul ^a,c   Loupy, Alexandre ^a,c   Lefaucheur, Carmen ^a,b  

^a INSERM   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

donor specific anti HLA antibody; interstitial fibrosis; kidney transplantation; outcome

Indexed keywords

CALCINEURIN INHIBITOR; HLA ANTIBODY; ALLOANTIBODY; COMPLEMENT C4D; COMPLEMENT COMPONENT C4B; HLA ANTIGEN; PEPTIDE FRAGMENT;

ACUTE KIDNEY TUBULE NECROSIS; ADULT; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ARTICLE; BK VIRUS INFECTION; COMPLEMENT DEPOSITION; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; GLOMERULOPATHY; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; KIDNEY ALLOGRAFT; KIDNEY ALLOGRAFT FIBROSIS; KIDNEY ALLOGRAFT REJECTION; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY TUBULAR ATROPHY; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PYELONEPHRITIS; RENAL GRAFT DYSFUNCTION; RISK FACTOR; URINARY TRACT DISEASE ASSESSMENT; AGE; AGED; ALLOGRAFT; ALLOTRANSPLANTATION; BIOPSY; BLOOD; DISEASE EXACERBATION; DONOR; FIBROSIS; GRAFT REJECTION; IMMUNOLOGY; KIDNEY TRANSPLANTATION; KIDNEY TUBULE; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; AGE FACTORS; AGED; ALLOGRAFTS; BIOPSY; COMPLEMENT C4B; DISEASE PROGRESSION; FEMALE; FIBROSIS; GRAFT REJECTION; GRAFT SURVIVAL; HLA ANTIGENS; HUMANS; ISOANTIBODIES; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; KIDNEY TUBULES; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 85019960686     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1016/j.kint.2017.03.033     Document Type: Article

References (77)

1. Rockey, D.C., Bell, P.D., Hill, J.A., Fibrosis—a common pathway to organ injury and failure. N Engl J Med 372 (2015), 1138–1149.
2. Nankivell, B.J., Borrows, R.J., Fung, C.L., et al. The natural history of chronic allograft nephropathy. N Engl J Med 349 (2003), 2326–2333.
3. Friedman, S.L., Mechanisms of hepatic fibrogenesis. Gastroenterology 134 (2008), 1655–1669.
4. Papadimitriou, J.C., Drachenberg, C.B., Klassen, D.K., et al. Histological grading of chronic pancreas allograft rejection/graft sclerosis. Am J Transplant 3 (2003), 599–605.
5. Solez, K., Colvin, R.B., Racusen, L.C., et al. Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 7 (2007), 518–526.
6. Li, C., Yang, C.W., The pathogenesis and treatment of chronic allograft nephropathy. Nat Rev Nephrol 5 (2009), 513–519.
7. Halloran, P.F., Melk, A., Barth, C., Rethinking chronic allograft nephropathy: the concept of accelerated senescence. J Am Soc Nephrol 10 (1999), 167–181.
8. Naesens, M., Lerut, E., de Jonge, H., et al. Donor age and renal P-glycoprotein expression associate with chronic histological damage in renal allografts. J Am Soc Nephrol 20 (2009), 2468–2480.
9. El-Zoghby, Z.M., Stegall, M.D., Lager, D.J., et al. Identifying specific causes of kidney allograft loss. Am J Transplant 9 (2009), 527–535.
10. Stegall, M.D., Park, W.D., Larson, T.S., et al. The histology of solitary renal allografts at 1 and 5 years after transplantation. Am J Transplant 11 (2011), 698–707.
11. Di Paolo, S., Stallone, G., Schena, A., et al. Hypertension is an independent predictor of delayed graft function and worse renal function only in kidneys with chronic pathological lesions. Transplantation 73 (2002), 623–627.
12. Heilman, R.L., Mathur, A., Smith, M.L., et al. Increasing the use of kidneys from unconventional and high-risk deceased donors. Am J Transplant 16 (2016), 3086–3092.
13. Perico, N., Cattaneo, D., Sayegh, M.H., Remuzzi, G., Delayed graft function in kidney transplantation. Lancet 364 (2004), 1814–1827.
14. Debout, A., Foucher, Y., Trebern-Launay, K., et al. Each additional hour of cold ischemia time significantly increases the risk of graft failure and mortality following renal transplantation. Kidney Int 87 (2015), 343–349.
15. Siedlecki, A., Irish, W., Brennan, D.C., Delayed graft function in the kidney transplant. Am J Transplant 11 (2011), 2279–2296.
16. Nankivell, B.J., Borrows, R.J., Fung, C.L., et al. Delta analysis of posttransplantation tubulointerstitial damage. Transplantation 78 (2004), 434–441.
17. Heilman, R.L., Smith, M.L., Smith, B.H., et al. Progression of interstitial fibrosis during the first year after deceased donor kidney transplantation among patients with and without delayed graft function. Clin J Am Soc Nephrol 11 (2016), 2225–2232.
18. Morozumi, K., Takeda, A., Uchida, K., Mihatsch, M.J., Cyclosporine nephrotoxicity: how does it affect renal allograft function and transplant morphology?. Transplant Proc 36:suppl 2 (2004), 251S–256S.
19. Busauschina, A., Schnuelle, P., van der Woude, F.J., Cyclosporine nephrotoxicity. Transplant Proc 36 (2004), 229S–233S.
20. Nankivell, B.J., Borrows, R.J., Fung, C.L., et al. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 78 (2004), 557–565.
21. Nankivell, B.J., P'Ng, C.H., O'Connell, P.J., Chapman, J.R., Calcineurin inhibitor nephrotoxicity through the lens of longitudinal histology: comparison of cyclosporine and tacrolimus eras. Transplantation 100 (2016), 1723–1731.
22. Buehrig, C.K., Lager, D.J., Stegall, M.D., et al. Influence of surveillance renal allograft biopsy on diagnosis and prognosis of polyomavirus-associated nephropathy. Kidney Int 64 (2003), 665–673.
23. Akioka, Y., Chikamoto, H., Horita, S., et al. Screening of vesicoureteral reflux in pediatric patients with kidney transplantation showing non-specific interstitial fibrosis and tubular atrophy with interstitial Tamm-Horsfall protein deposits in protocol allograft biopsy. Clin Transplant 23:suppl 20 (2009), 2–5.
24. Lorenz, E.C., Cosio, F.G., The impact of urinary tract infections in renal transplant recipients. Kidney Int 78 (2010), 719–721.
25. Liptak, P., Kemeny, E., Ivanyi, B., Primer: histopathology of polyomavirus-associated nephropathy in renal allografts. Nat Clin Pract Nephrol 2 (2006), 631–636.
26. Meehan, S.M., Kadambi, P.V., Manaligod, J.R., et al. Polyoma virus infection of renal allografts: relationships of the distribution of viral infection, tubulointerstitial inflammation, and fibrosis suggesting viral interstitial nephritis in untreated disease. Hum Pathol 36 (2005), 1256–1264.
27. Inigo, P., Campistol, J.M., Lario, S., et al. Effects of losartan and amlodipine on intrarenal hemodynamics and TGF-beta(1) plasma levels in a crossover trial in renal transplant recipients. J Am Soc Nephrol 12 (2001), 822–827.
28. Kusaka, M., Mackenzie, H.S., Ziai, F., et al. Recipient hypertension potentiates chronic functional and structural injury of rat renal allografts. Transplantation 74 (2002), 307–314.
29. Naesens, M., Kuypers, D.R., De Vusser, K., et al. The histology of kidney transplant failure: a long-term follow-up study. Transplantation 98 (2014), 427–435.
30. Gloor, J.M., Cosio, F.G., Rea, D.J., et al. Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation. Am J Transplant 6 (2006), 1841–1847.
31. El Ters, M., Grande, J.P., Keddis, M.T., et al. Kidney allograft survival after acute rejection, the value of follow-up biopsies. Am J Transplant 13 (2013), 2334–2341.
32. Heilman, R.L., Devarapalli, Y., Chakkera, H.A., et al. Impact of subclinical inflammation on the development of interstitial fibrosis and tubular atrophy in kidney transplant recipients. Am J Transplant 10 (2010), 563–570.
33. Ogino, S., Nishihara, R., VanderWeele, T.J., et al. Review article: the role of molecular pathological epidemiology in the study of neoplastic and non-neoplastic diseases in the era of precision medicine. Epidemiology 27 (2016), 602–611.
34. Kapitsinou, P.P., Sano, H., Michael, M., et al. Endothelial HIF-2 mediates protection and recovery from ischemic kidney injury. J Clin Invest 124 (2014), 2396–2409.
35. Vasko, R., Xavier, S., Chen, J., et al. Endothelial sirtuin 1 deficiency perpetrates nephrosclerosis through downregulation of matrix metalloproteinase-14: relevance to fibrosis of vascular senescence. J Am Soc Nephrol 25 (2014), 276–291.
36. Zeisberg, E.M., Potenta, S.E., Sugimoto, H., et al. Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J Am Soc Nephrol 19 (2008), 2282–2287.
37. Duffield, J.S., Cellular and molecular mechanisms in kidney fibrosis. J Clin Invest 124 (2014), 2299–2306.
38. LeBleu, V.S., Taduri, G., O'Connell, J., et al. Origin and function of myofibroblasts in kidney fibrosis. Nat Med 19 (2013), 1047–1053.
39. Babickova, J., Klinkhammer, B.M., Buhl, E.M., et al. Regardless of etiology, progressive renal disease causes ultrastructural and functional alterations of peritubular capillaries. Kidney Int 91 (2017), 70–85.
40. Devresse, A., Aydin, S., Le Quintrec, M., et al. Complement activation and effect of eculizumab in scleroderma renal crisis. Medicine (Baltimore), 95, 2016, e4459.
41. Mouthon, L., Mehrenberger, M., Teixeira, L., et al. Endothelin-1 expression in scleroderma renal crisis. Hum Pathol 42 (2011), 95–102.
42. Tan, Y., Yu, F., Liu, G., Diverse vascular lesions in systemic lupus erythematosus and clinical implications. Curr Opin Nephrol Hypertens 23 (2014), 218–223.
43. Yu, F., Wu, L.H., Tan, Y., et al. Tubulointerstitial lesions of patients with lupus nephritis classified by the 2003 International Society of Nephrology and Renal Pathology Society system. Kidney Int 77 (2010), 820–829.
44. Yung S, Chan TM. Anti-dsDNA antibodies and resident renal cells—their putative roles in pathogenesis of renal lesions in lupus nephritis [e-pub ahead of print]. Clin Immunol. http://dx.doi.org/10.1016/j.clim.2016.09.002. Accessed September 6, 2016.
45. Berthier, C.C., Bethunaickan, R., Gonzalez-Rivera, T., et al. Cross-species transcriptional network analysis defines shared inflammatory responses in murine and human lupus nephritis. J Immunol 189 (2012), 988–1001.
46. Sis, B., Jhangri, G.S., Bunnag, S., et al. Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am J Transplant 9 (2009), 2312–2323.
47. Phillips, S., Kapp, M., Crowe, D., et al. Endothelial activation, lymphangiogenesis, and humoral rejection of kidney transplants. Hum Pathol 51 (2016), 86–95.
48. Loupy, A., Vernerey, D., Viglietti, D., et al. Determinants and outcomes of accelerated arteriosclerosis: major impact of circulating antibodies. Circ Res 117 (2015), 470–482.
49. Zhang, X., Reed, E.F., Effect of antibodies on endothelium. Am J Transplant 9 (2009), 2459–2465.
50. Sellares, J., de Freitas, D.G., Mengel, M., et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 12 (2012), 388–399.
51. Lefaucheur, C., Loupy, A., Vernerey, D., et al. Antibody-mediated vascular rejection of kidney allografts: a population-based study. Lancet 381 (2013), 313–319.
52. Mohan, S., Palanisamy, A., Tsapepas, D., et al. Donor-specific antibodies adversely affect kidney allograft outcomes. J Am Soc Nephrol 23 (2012), 2061–2071.
53. Loupy, A., Haas, M., Solez, K., et al. The Banff 2015 Kidney meeting report: Current challenges in rejection classification and prospects for adopting molecular pathology. Am J Transplant 17 (2017), 28–41.
54. Ziegler, M.E., Souda, P., Jin, Y.P., et al. Characterization of the endothelial cell cytoskeleton following HLA class I ligation. PLoS One, 7, 2012, e29472.
55. Jin, Y.P., Singh, R.P., Du, Z.Y., et al. Ligation of HLA class I molecules on endothelial cells induces phosphorylation of Src, paxillin, and focal adhesion kinase in an actin-dependent manner. J Immunol 168 (2002), 5415–5423.
56. Smith, R.N., Kawai, T., Boskovic, S., et al. Four stages and lack of stable accommodation in chronic alloantibody-mediated renal allograft rejection in Cynomolgus monkeys. Am J Transplant 8 (2008), 1662–1672.
57. Steegh, F.M., Gelens, M.A., Nieman, F.H., et al. Early loss of peritubular capillaries after kidney transplantation. J Am Soc Nephrol 22 (2011), 1024–1029.
58. Xu-Dubois, Y.C., Peltier, J., Brocheriou, I., et al. Markers of endothelial-to-mesenchymal transition: evidence for antibody-endothelium interaction during antibody-mediated rejection in kidney recipients. J Am Soc Nephrol 27 (2016), 324–332.
59. Farris, A.B., Colvin, R.B., Renal interstitial fibrosis: mechanisms and evaluation. Curr Opin Nephrol Hypertens 21 (2012), 289–300.
60. Colvin, R.B., Smith, R.N., Antibody-mediated organ-allograft rejection. Nat Rev Immunol 5 (2005), 807–817.
61. Bhattacharyya, S., Wei, J., Varga, J., Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat Rev Rheumatol 8 (2011), 42–54.
62. Woodworth, T.G., Suliman, Y.A., Furst, D.E., Clements, P., Scleroderma renal crisis and renal involvement in systemic sclerosis. Nat Rev Nephrol 12 (2016), 678–691.
63. Dragun, D., Catar, R., Philippe, A., Non-HLA antibodies against endothelial targets bridging allo- and autoimmunity. Kidney Int 90 (2016), 280–288.
64. Cardinal, H., Dieude, M., Hebert, M.J., The emerging importance of non-HLA autoantibodies in kidney transplant complications. J Am Soc Nephrol 28 (2017), 400–406.
65. Modena, B.D., Kurian, S.M., Gaber, L.W., et al. Gene expression in biopsies of acute rejection and interstitial fibrosis/tubular atrophy reveals highly shared mechanisms that correlate with worse long-term outcomes. Am J Transplant 16 (2016), 1982–1998.
66. Lefaucheur, C., Viglietti, D., Bentlejewski, C., et al. IgG donor-specific anti-human HLA antibody subclasses and kidney allograft antibody-mediated injury. J Am Soc Nephrol 27 (2016), 293–304.
67. O'Connell, P.J., Zhang, W., Menon, M.C., et al. Biopsy transcriptome expression profiling to identify kidney transplants at risk of chronic injury: a multicentre, prospective study. Lancet 388 (2016), 983–993.
68. Halloran, P.F., Famulski, K.S., Reeve, J., Molecular assessment of disease states in kidney transplant biopsy samples. Nat Rev Nephrol 12 (2016), 534–548.
69. Famulski, K.S., Reeve, J., de Freitas, D.G., et al. Kidney transplants with progressing chronic diseases express high levels of acute kidney injury transcripts. Am J Transplant 13 (2013), 634–644.
70. Wiebe, C., Gibson, I.W., Blydt-Hansen, T.D., et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant 12 (2012), 1157–1167.
71. Archdeacon, P., Chan, M., Neuland, C., et al. Summary of FDA antibody-mediated rejection workshop. Am J Transplant 11 (2011), 896–906.
72. Vo, A.A., Lukovsky, M., Toyoda, M., et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 359 (2008), 242–251.
73. Racusen, L.C., Solez, K., Colvin, R.B., et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 55 (1999), 713–723.
74. Haas, M., Sis, B., Racusen, L.C., et al. Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant 14 (2014), 272–283.
75. Lefaucheur, C., Loupy, A., Hill, G.S., et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 21 (2010), 1398–1406.
76. Greenland, S., Drescher, K., Maximum likelihood estimation of the attributable fraction from logistic models. Biometrics 49 (1993), 865–872.
77. Cleveland, W.S., Devlin, S.J., Locally weighted regression: an approach to regression analysis by local fitting. J Am Stat Assoc 83 (1988), 596–610.